[ad_1]
What I Wish I Knew a Year Ago About the Aesthetic Market and Where I’m Investing Now
VANCOUVER, BC, April 16, 2022 /PRNewswire/ — In 1978, scientists isolated human insulin produced by genetically modified E. colimarking the first biopharmaceutical derived from recombinant DNA technology. This radically new methodology for isolating enzymes and active ingredients shook biotechnology to the core, triggering a tsunami of discoveries. Since then, more than 250 therapeutic proteins and monoclonal antibodies have stolen the stage as standard of care.
In the last several years, this momentum carried over to cosmetics, as biotechnology and aesthetic medicines joined forces to isolate anti-aging skin products such as hyaluronic acid, kojic acid, and resveratrol, to name a few. But what new developments stand on the horizon? And to which direction should investors hone their gaze? Two emerging therapies, stem cell exosomes and gene therapy, scintillate brightly on the financial horizon as golden investment opportunities.
The global biotech aesthetic market…
Full story available on Benzinga.com
[ad_2]
Source link
